The risk of symptomatic pulmonary embolism due to proximal deep venous thrombosis differs in patients with different types of inherited thrombophilia

Summary

It is uncertain whether the presence of inherited thrombophilia influences the risk of developing symptomatic pulmonary embolism (PE) and whether different thrombophilic alterations are associated with different risks of symptomatic PE. To investigate such issue, we retrospectively studied 920 patients with proximal deep vein thrombosis (DVT) of the legs with or without symptomatic PE referred for thrombophilia screening; patients with overt cancer or antiphospholipid antibodies had been excluded. Three hundred fifty-four patients (38.5%) had deficiency of antithrombin (AT, n=16), protein C (PC, n=26), protein S (PS, n=22), factor V Leiden (FVL, n=168), prothrombin G20210A (PT-GA, n=87), or multiple abnormalities (n=35), and 566 had none of the studied thrombophilic abnormalities. Symptomatic PE complicated the first DVT in 242 patients (26%); the risk of PE was increased in patients with AT deficiency (relative risk [RR] 2.4, 95% confidence interval [CI] 1.6–3.6) or with PT-GA (RR 1.5, 95%CI 1.1–2.0) and decreased in those with FVL (RR 0.7, 95%CI 0.5–1.0) in comparison with those with unknown inherited defect. These data suggest that patients with proximal DVT have different risks of symptomatic PE according to the type of inherited thrombophilia.

Keywords

Venous thrombosis - pulmonary embolism - antithrombin deficiency - factor V Leiden - prothrombin G20210A

• References

• 1 Silverstein MD, Heit JA, Mohr DN. et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998; 158: 585-593.
• 2 Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999; 353: 1386-1389.
• 3 Kucher N, Tapson VF, Goldhaber SZ. et al. Risk factors associated with symptomatic pulmonary embolism in a large cohort of deep vein thrombosis patients. Thromb Haemost 2005; 93: 494-498.
• 4 Naess IA, Christiansen SC, Romundstad P. et al. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 2007; 5: 1-8.
• 5 De Stefano V, Rossi E, Za T. et al. Prophylaxis and treatment of venous thromboembolism in individuals with inherited thrombophilia. Semin Thromb Hemost 2006; 32: 767-780.
• 6 Desmarais S, de Moerloose P, Reber G. et al. Resistance to activated protein C in an unselected population of patients with pulmonary embolism. Lancet 1996; 347: 1374-1375.
• 7 Manten B, Westendorp RGJ, Koster T. et al. Risk factor profiles in patients with different clinical manifestations of venous thromboembolism: a focus on the factor V Leiden mutation. Thromb Haemost 1996; 76: 510-513.
• 8 Martinelli I, Cattaneo M, Panzeri D. et al. Low prevalence of factor V:Q506 in 41 patients with isolated pulmonary embolism. Thromb Haemost 1997; 77: 440-443.
• 9 Baglin TP, Brown K, Williamson D. et al. Relative risk of pulmonary embolism and deep vein thrombosis in association with the factor V Leiden in a United Kingdom population. Thromb Haemost 1997; 77: 1219.
• 10 Turkstra F, Karemaker R, Kuijer PM. et al. Is the prevalence of the factor V Leiden mutation in patients with pulmonary embolism and deep vein thrombosis really different?. Thromb Haemost 1999; 81: 345-348.
• 11 De Moerloose P, Reber G, Perrier A. et al. Prevalence of factor V Leiden and prothrombin G20210A mutations in unselected patients with venous thromboembolism. Br J Haematol 2000; 110: 125-129.
• 12 Margaglione M, Brancaccio V, De Lucia D. et al. Inherited thrombophilic risk factors and venous thromboembolism: distinct role in peripheral deep venous thrombosis and pulmonary embolism. Chest 2000; 118: 1405-1411.
• 13 Meyer G, Emmerich J, Helley D. et al. Factors V Leiden and II 20210A in patients with symptomatic pulmonary embolism and deep vein thrombosis. Am J Med 2001; 110: 12-15.
• 14 Martinelli I, Battaglioli T, Razzari C. et al. Type and location of venous thromboembolism in patients with factor V Leiden or prothrombin G20210A and in those with no thrombophilia. J Thromb Haemost 2007; 5: 98-101.
• 15 Leroyer C, Mercier B, Escoffre M. et al. Factor V Leiden prevalence in venous thromboembolism patients. Chest 1997; 111: 1603-1606.
• 16 De Stefano V, Martinelli I, Mannucci PM. et al. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med 1999; 341: 801-806.
• 17 Bounameaux H. Factor V Leiden paradox: risk of deep-vein thrombosis but not of pulmonary embolism. Lancet 2000; 356: 182-183.
• 18 Kearon C. Natural history of venous thromboembolism. Circulation 2003; 107 (Suppl. 23) I-22-30.
• 19 Bajzar L, Kalafatis M, Simioni P. et al. An antifibrinolytic mechanism describing the prothrombotic effect associated with factor V Leiden. J Biol Chem 1996; 271: 22949-22952
• 20 Parker AC, Mundada LV, Schmaier AH. et al. Factor V Leiden inhibits fibrinolysis in vivo. Circulation 2004; 110: 3594-3598.
• 21 Mosnier LO, Bouma BN. Regulation of fibrinolysis by thrombin activatable fibrinolysis inhibitor, an unstable carboxypeptidase B that unites the pathways of coagulation and fibrinolysis. Arterioscler Thromb Vasc Biol 2006; 26: 2445-2453.
• 22 Colucci M, Binetti BM, Tripodi A. et al. Hyperprothrombinemia associated with prothrombin G20210A mutation inhibits plasma fibrinolysis through a TAFImediated mechanism. Blood 2004; 103: 2157-2161.
• 23 Machovic R, Bauer PI, Arànyi P. et al. Kinetic analysis of the heparin-enhanced plasmin-antithrombin III reaction. Apparent catalytic role of heparin. Biochem J 1981; 199: 521-526.
• 24 Patston PA, Schapira M. Low-affinity heparin stimulates the inactivation of plasminogen activator inhibitor-1 by thrombin. Blood 1994; 84: 1164-1172.